Poorly differentiated chordoma: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

All cases

2 options

Maximal safe resection and proton radiotherapy as on the chordoma page; EZH2 inhibition under study for SMARCB1-deficient tumours.

The options, in plain words

Proton therapyEstablished

Radiation using protons, which stop inside the tumour instead of passing through, so tissue behind it gets no dose.

No exit dose; lower integral dose
Reduced second cancers in children

TazemetostatWithdrawnSmall-molecule EZH2 inhibitor

Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.

Also referenced:Chordoma

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Proton therapy

Cost
Range uncertainty
Limited randomised evidence in adults

Questions to ask about this decision

Between Proton therapy and Tazemetostat, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (all cases), which of the standard options do you recommend and why?
Why: Guideline options include: Maximal safe resection and proton radiotherapy as on the chordoma page; EZH2 inhibition under study for SMARCB1-deficient tumours.
Am I a candidate for Tazemetostat, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care